Tabrecta (Capmatinib) 200mg x 60 Tablets - Product Description
Tabrecta, also known by its generic name Capmatinib, is an oral medication used for the treatment of certain types of non-small cell lung cancer (NSCLC) that are associated with MET exon 14 alterations. This targeted therapy works by inhibiting the MET receptor tyrosine kinase, which plays a crucial role in the growth and spread of cancer cells.

Indications
Tabrecta is indicated for adult patients with metastatic NSCLC that is positive for MET exon 14 alterations as detected by an Clinically Approved Pharmaceuticals test. It is prescribed for patients who have not received prior treatment or have progressed on prior therapies.

Dosage and Administration
The recommended dosage of Tabrecta is 200 mg taken orally twice daily with or without food. It is important to take the medication at the same times each day to maintain even levels in the bloodstream.

Side Effects
Common side effects of Tabrecta may include:

Nausea
Fatigue
Diarrhea
Swelling (edema)
Loss of appetite

Patients should report any severe side effects to their healthcare provider immediately.

Warnings and Precautions
Before starting Tabrecta, patients should inform their healthcare provider of any existing medical conditions, especially liver problems, as dosage adjustments may be necessary. Regular monitoring of liver function is recommended during treatment.

Drug Interactions
Capmatinib may interact with other medications, including certain antifungals, antibiotics, and anti-seizure medications. Patients should provide a list of all medications they are taking to their healthcare provider to avoid potential interactions.

Storage
Store Tabrecta at room temperature, away from moisture and heat. Keep out of reach of children and pets.

Conclusion
Tabrecta (Capmatinib) is a promising treatment option for patients with specific types of non-small cell lung cancer. As with any medication, it is essential to follow the healthcare provider's instructions and report any adverse effects promptly.